| Chapter title |
Multi-gene Panel Testing in Breast Cancer Management
|
|---|---|
| Chapter number | 8 |
| Book title |
Optimizing Breast Cancer Management
|
| Published in |
Cancer treatment and research, January 2018
|
| DOI | 10.1007/978-3-319-70197-4_8 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-970195-0, 978-3-31-970197-4
|
| Authors |
Christos Fountzilas, Virginia G. Kaklamani |
| Abstract |
Hereditary predisposition accounts for approximately 10% of all breast cancers and is mostly associated with germline mutations in high-penetrance genes encoding for proteins participating in DNA repair through homologous recombination (BRCA1 and BRCA2). With the advent of massive parallel next-generation DNA sequencing, simultaneous analysis of multiple genes with a short turnaround time and at a low cost has become possible. The clinical validity and utility of multi-gene panel testing is getting better characterized as more data on the significance of moderate-penetrance genes are collected from large, cancer genetic testing studies. In this chapter, we attempt to provide a general guide for interpretation of panel gene testing in breast cancer and use of the information obtained for clinical decision-making. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 10% |
| Student > Doctoral Student | 4 | 10% |
| Student > Ph. D. Student | 4 | 10% |
| Other | 3 | 8% |
| Student > Bachelor | 3 | 8% |
| Other | 8 | 20% |
| Unknown | 14 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 28% |
| Biochemistry, Genetics and Molecular Biology | 8 | 20% |
| Agricultural and Biological Sciences | 2 | 5% |
| Nursing and Health Professions | 1 | 3% |
| Social Sciences | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 16 | 40% |